AI-Powered Myasthenia Gravis Research

Myasthenia gravis is an autoimmune neuromuscular disease caused by antibodies against the acetylcholine receptor. AI agents research complement inhibitors, FcRn blockers, and targeted immunotherapies.

Standard of Care

Acetylcholinesterase inhibitors (pyridostigmine), corticosteroids, steroid-sparing immunosuppressants (azathioprine, mycophenolate), IVIg/plasmapheresis (crises), thymectomy.

Prevalence

~60,000–80,000 Americans affected. Can occur at any age. Bimodal: women 20–30, men 60–70.

Key Biomarkers

• AChR antibodies (85% of generalized MG)
• MuSK antibodies
• LRP4 antibodies
• Repetitive nerve stimulation (decrement)
• Single-fiber EMG

Emerging Research

Complement inhibitors: eculizumab, ravulizumab (approved for AChR+ generalized MG), zilucoplan (subcutaneous C5 inhibitor). FcRn blockers: efgartigimod (Vyvgart), rozanolixizumab — rapidly reduce pathogenic antibodies. These represent the biggest MG therapy advancement in decades. Targeted B-cell therapies (rituximab highly effective in MuSK-MG).

Frequently Asked Questions

What are FcRn blockers for MG?

FcRn (neonatal Fc receptor) recycles IgG antibodies, maintaining their long half-life. FcRn blockers (efgartigimod/Vyvgart) accelerate IgG degradation, rapidly reducing pathogenic AChR antibodies. In trials, efgartigimod improved MG symptoms within 1–2 weeks. It's a targeted alternative to IVIg/plasmapheresis.

Why is thymectomy done for MG?

The thymus plays a central role in MG pathogenesis — thymic abnormalities (hyperplasia, thymoma) are common. The MGTX trial showed thymectomy + prednisone was superior to prednisone alone, with lower steroid requirements and better outcomes at 3 years. It's recommended for AChR+ generalized MG patients aged 18–65.